NEW YORK (GenomeWeb) – A new, integrated omics study has uncovered an unexpectedly diverse set of molecular processes that can go awry in a rare and aggressive form of gynecological cancer called uterine carcinosarcoma.
“The biggest surprise was the genetic variety within tumors of this type,” co-corresponding author Douglas Levine, gynecologic oncology director at the New York University Langone Medical Center’s Laura and Isaac Perlmutter Cancer Center, said in a statement, noting that “we can [now] apply what we’ve learned to creating more specific clinical trials.”
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?